Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE202 in mild-to-moderate ulcerative colitis
NL-OMON52361Phase 2Not yet recruiting
- Sponsor
- Vedanta Biosciences
- Start
- Oct 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VE202 in autoimmune colitis (2 arms), sponsored by Vedanta Biosciences. Primary endpoints: Endoscopic response rate at Day 56 after 8 weeks of treatment and Safety in Part 1 and Part 2. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
VE202
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON52361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52361.